波士顿科学(BSX.US)将以3.6亿美元预付款收购医疗设备商SoniVie

智通财经
03 Mar

智通财APP获悉,波士顿科学(BSX.US)已同意以约3.6亿美元的预付款收购医疗设备公司SoniVie。

作为SoniVie的战略投资者,波士顿科学目前持有SoniVie约10%的股权。这笔交易包括预付约3.6亿美元购买剩余90%尚未拥有的股份,以及在达到监管里程碑后支付高达1.8亿美元。

该交易将拓展波士顿科学的介入心脏病治疗产品。

SoniVie的主要产品TIVUS是一种实验性血管内治疗方法,旨在去除血管周围的神经以治疗各种高血压疾病,包括肾动脉去交感神经术(RDN)。

波士顿科学预计该交易将于2025年上半年完成。该公司预计此次交易将略微摊薄2025年调整后每股收益,并通过内部成本效率和交易来抵消这一影响。

截至发稿,波士顿科学盘前涨近1%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10